Where does Agios Pharmaceuticals's cash flow data come from?

Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$99.11M+8.3%	-$108.04M-4.5%	-$103.43M+7.7%	-$112.02M-25.5%	-$89.29M—
Depreciation and amortization	$1.36M+7.7%	$1.27M-7.9%	$1.37M+9.1%	$1.26M-1.5%	$1.28M-6.5%
Stock-based compensation	$15.54M+10.0%	$14.12M+14.1%	$12.38M-15.8%	$14.69M+29.3%	$11.36M+4.2%
Change in accounts receivable	$5.56M+0.1%	$5.55M+12,802%	$43K-97.4%	$1.64M+315%	-$765K-177%
Change in inventories	$2.17M+145%	$886K-25.3%	$1.19M-4.6%	$1.24M-37.5%	$1.99M+67.6%
Change in accounts payable	-$4.99M—	——	$1.81M-53.7%	$3.91M+238%	-$2.82M—
Change in accrued liabilities	-$19.17M—	——	——	——	-$26.1M-293%
Change in other assets	$2.46M+160%	$945K—	——	$1.62M-23.6%	$2.12M+124%
Change in income taxes payable/receivable	$0—	——	——	-$683K-263%	-$188K—
Non-cash operating lease expense	$3.26M+1.9%	$3.2M+1.9%	$3.14M+1.9%	$3.08M+1.9%	$3.02M+1.9%
Change in operating lease liabilities	-$4.46M-3.6%	-$4.31M-1.5%	-$4.25M-1.6%	-$4.18M-3.3%	-$4.05M-5.3%
Net cash from operating activities	-$118.92M-23.6%	-$96.21M-9.1%	-$88.15M-14.3%	-$77.12M+30.8%	-$111.49M+16.3%
Capital expenditures	$769K-31.3%	$1.12M-28.0%	$1.56M+77.7%	$875K+14.2%	$766K-20.8%
Purchases of investments	$148.18M-8.0%	$161.08M-7.9%	$174.98M+33.8%	$130.8M-25.2%	$174.9M-11.8%
Proceeds from maturities/sales of investments	$290.26M+15.1%	$252.27M-7.3%	$272.09M+23.3%	$220.64M-23.5%	$288.26M+92.0%
Net cash from investing activities	$141.31M+56.9%	$90.08M-5.7%	$95.56M+21.0%	$78.97M-29.9%	$112.59M—
Proceeds from issuance of common stock	$2.08M-18.7%	$2.56M-42.3%	$4.44M+6,723%	$65K-96.0%	$1.62M-66.6%
Net cash from financing activities	$2.08M-18.7%	$2.56M-42.3%	$4.44M+6,723%	$65K-96.0%	$1.62M-66.6%
Net increase (decrease) in cash	$24.47M—	——	$11.84M+521%	$1.91M-29.8%	$2.72M+102%
Income taxes paid	$4K—	——	$65K-95.1%	$1.32M+599%	$188K-99.6%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.14M-34.7%	$1.75M+4.7%	$1.67M-30.8%	$2.42M+79.5%	$1.35M-76.0%
Accrued expenses and other liabilities	-$19.17M—	——	——	——	-$26.1M-293%
Operating lease liabilities	-$4.46M-3.6%	-$4.31M-1.5%	-$4.25M-1.6%	-$4.18M-3.3%	-$4.05M-5.3%
Increase (Decrease) in Prepaid Expense and Other Assets	$2.46M+160%	$945K—	——	$1.62M-23.6%	$2.12M+124%
Operating lease right-of-use asset amortization	$3.26M+1.9%	$3.2M+1.9%	$3.14M+1.9%	$3.08M+1.9%	$3.02M+1.9%
Depreciation and amortization	$1.36M+7.7%	$1.27M-7.9%	$1.37M+9.1%	$1.26M-1.5%	$1.28M-6.5%
Net realized gains (losses)	$28K-76.3%	$118K+6,000%	-$2K—	$0-100%	$2K—
Proceeds From Sale And Maturity Of Available For Sale Securities	$290.26M+15.1%	$252.27M-7.3%	$272.09M+23.3%	$220.64M-23.5%	$288.26M+92.0%
Proceeds from exercises of stock options and other stock issuances	$2.08M-18.7%	$2.56M-42.3%	$4.44M+6,723%	$65K-96.0%	$1.62M-66.6%
Accrued payables for capital expenditures	$668K—	——	$214K—	——	$221K-13.7%
Increase Decrease In Operating Lease Liability	-$4.46M-3.6%	-$4.31M-1.5%	-$4.25M-1.6%	-$4.18M-3.3%	-$4.05M-5.3%
Income Taxes Paid, Net	$4K—	——	$65K-95.1%	$1.32M+599%	$188K-99.6%
Free cash flow	-$119.69M-23.0%	-$97.33M-8.5%	-$89.71M-15.0%	-$78M+30.5%	-$112.26M+16.3%
Free cash flow	-$119.69M-23.0%	-$97.33M-8.5%	-$89.71M-15.0%	-$78M+30.5%	-$112.26M+16.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Agios Pharmaceuticals's cash flow data come from?: Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.